Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totalling 12,730,000 shares, a decline of 17.9% from the June 30th total of 15,510,000 shares. Based on an average daily volume of 6,250,000 shares, the days-to-cover ratio is presently 2.0 days.

Sangamo Therapeutics Stock Up 28.7 %

SGMO traded up $0.19 during mid-day trading on Friday, reaching $0.86. 123,708,543 shares of the company traded hands, compared to its average volume of 18,010,276. The stock has a market capitalization of $179.48 million, a P/E ratio of -0.46 and a beta of 1.24. The company’s fifty day moving average price is $0.49 and its 200-day moving average price is $0.61. Sangamo Therapeutics has a 52-week low of $0.29 and a 52-week high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same quarter in the prior year, the firm posted $0.12 earnings per share. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on SGMO. StockNews.com assumed coverage on Sangamo Therapeutics in a research report on Sunday. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Hold” and a consensus target price of $5.67.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP increased its stake in shares of Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after purchasing an additional 7,734,400 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after buying an additional 192,385 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Sangamo Therapeutics by 14.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 129,811 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 1st quarter valued at about $331,000. Finally, Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 34,960 shares during the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.